Successful Portfolios LLC Takes $215,000 Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Successful Portfolios LLC acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the fourth quarter, HoldingsChannel reports. The fund acquired 637 shares of the medical equipment provider’s stock, valued at approximately $215,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ausdal Financial Partners Inc. grew its position in Intuitive Surgical by 1.5% during the fourth quarter. Ausdal Financial Partners Inc. now owns 2,192 shares of the medical equipment provider’s stock worth $739,000 after buying an additional 33 shares in the last quarter. Modera Wealth Management LLC lifted its stake in shares of Intuitive Surgical by 2.0% in the 3rd quarter. Modera Wealth Management LLC now owns 1,715 shares of the medical equipment provider’s stock valued at $501,000 after acquiring an additional 34 shares during the last quarter. Pure Financial Advisors LLC lifted its stake in shares of Intuitive Surgical by 2.4% in the 4th quarter. Pure Financial Advisors LLC now owns 1,432 shares of the medical equipment provider’s stock valued at $483,000 after acquiring an additional 34 shares during the last quarter. Arthur M. Cohen & Associates LLC lifted its stake in shares of Intuitive Surgical by 0.4% in the 4th quarter. Arthur M. Cohen & Associates LLC now owns 8,850 shares of the medical equipment provider’s stock valued at $2,986,000 after acquiring an additional 34 shares during the last quarter. Finally, Prime Capital Investment Advisors LLC raised its position in Intuitive Surgical by 2.2% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 1,702 shares of the medical equipment provider’s stock worth $497,000 after purchasing an additional 37 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the transaction, the vice president now directly owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $370.20, for a total transaction of $740,400.00. Following the completion of the transaction, the director now directly owns 25,319 shares in the company, valued at $9,373,093.80. The disclosure for this sale can be found here. Insiders sold a total of 248,418 shares of company stock valued at $95,927,097 in the last three months. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Down 0.3 %

NASDAQ ISRG traded down $1.01 on Thursday, reaching $399.09. The company had a trading volume of 1,098,436 shares, compared to its average volume of 1,673,439. The stock has a market capitalization of $141.46 billion, a PE ratio of 79.30, a price-to-earnings-growth ratio of 6.17 and a beta of 1.36. The firm’s 50 day moving average price is $385.19 and its 200 day moving average price is $332.83. Intuitive Surgical, Inc. has a 12 month low of $246.63 and a 12 month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.48 by $0.12. The firm had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.89 billion. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The business’s quarterly revenue was up 16.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.91 EPS. On average, research analysts expect that Intuitive Surgical, Inc. will post 4.93 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ISRG shares. Piper Sandler increased their price target on Intuitive Surgical from $325.00 to $425.00 and gave the stock an “overweight” rating in a report on Wednesday, January 24th. Mizuho lifted their price target on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research note on Thursday, January 25th. Wells Fargo & Company lifted their price target on Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research note on Friday, January 19th. Royal Bank of Canada lifted their target price on shares of Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 24th. Finally, Truist Financial lifted their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $371.60.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.